Rhenman & Partners Asset Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20.3M | Buy |
41,340
+7,700
| +23% | +$4.18M | 2.51% | 7 |
|
|
2025
Q4 | $19.5M | Buy |
33,640
+3,600
| +12% | +$2.04M | 1.82% | 17 |
|
|
2025
Q3 | $14.6M | Buy |
30,040
+18,900
| +170% | +$8.8M | 1.61% | 24 |
|
|
2025
Q2 | $4.52M | Sell |
11,140
-1,500
| -12% | -$627K | 0.57% | 53 |
|
|
2025
Q1 | $6.29M | Sell |
12,640
-3,000
| -19% | -$1.62M | 0.72% | 43 |
|
|
2024
Q4 | $8.14M | Sell |
15,640
-9,460
| -38% | -$5.2M | 0.84% | 44 |
|
|
2024
Q3 | $15.5M | Buy |
25,100
+1,100
| +5% | +$651K | 1.26% | 25 |
|
|
2024
Q2 | $13.3M | Buy |
24,000
+11,000
| +85% | +$6.3M | 1.27% | 28 |
|
|
2024
Q1 | $7.56M | Sell |
13,000
-20,500
| -61% | -$11.5M | 0.72% | 48 |
|
|
2023
Q4 | $17.8M | Buy |
33,500
+33,000
| +6,600% | +$16M | 1.78% | 20 |
|
|
2023
Q3 | $253K | Hold |
500
| – | – | 0.03% | 85 |
|
|
2023
Q2 | $261K | Sell |
500
-40,500
| -99% | -$21.9M | 0.03% | 83 |
|
|
2023
Q1 | $23.1M | Buy |
41,000
+1,000
| +3% | +$564K | 2.53% | 13 |
|
|
2022
Q4 | $22M | Sell |
40,000
-12,500
| -24% | -$6.62M | 2.3% | 12 |
|
|
2022
Q3 | $27M | Buy |
52,500
+15,400
| +42% | +$8.62M | 2.83% | 5 |
|
|
2022
Q2 | $20.2M | Buy |
37,100
+13,350
| +56% | +$7.35M | 2.29% | 14 |
|
|
2022
Q1 | $14M | Sell |
23,750
-20,250
| -46% | -$11.6M | 1.38% | 30 |
|
|
2021
Q4 | $29.3M | Sell |
44,000
-16,000
| -27% | -$9.99M | 1.95% | 16 |
|
|
2021
Q3 | $34.3M | Buy |
60,000
+10,000
| +20% | +$5.49M | 2.41% | 9 |
|
|
2021
Q2 | $25.2M | Buy |
50,000
+5,000
| +11% | +$2.36M | 1.71% | 16 |
|
|
2021
Q1 | $20.5M | Buy |
45,000
+17,550
| +64% | +$8.38M | 1.43% | 30 |
|
|
2020
Q4 | $12.8M | Sell |
27,450
-2,550
| -9% | -$1.2M | 1.04% | 41 |
|
|
2020
Q3 | $13.2M | Buy |
30,000
+11,000
| +58% | +$4.54M | 1.18% | 37 |
|
|
2020
Q2 | $6.88M | Hold |
19,000
| – | – | 0.74% | 51 |
|
|
2020
Q1 | $5.39M | Buy |
+19,000
| New | +$5.99M | 0.75% | 51 |
|
|
2019
Q4 | – | Sell |
-38,000
| Closed | -$11.1M | – | 100 |
|
|
2019
Q3 | $11.1M | Buy |
38,000
+8,200
| +28% | +$2.35M | 1.39% | 29 |
|
|
2019
Q2 | $8.75M | Sell |
29,800
-200
| -0.7% | -$55.1K | 0.96% | 42 |
|
|
2019
Q1 | $8.21M | Hold |
30,000
| – | – | 0.96% | 47 |
|
|
2018
Q4 | $6.71M | Buy |
+30,000
| New | +$7.04M | 0.77% | 51 |
|
|
2017
Q3 | – | Sell |
-25,000
| Closed | -$4.36M | – | 106 |
|
|
2017
Q2 | $4.36M | Sell |
25,000
-15,000
| -38% | -$2.52M | 0.63% | 58 |
|
|
2017
Q1 | $6.14M | Sell |
40,000
-5,000
| -11% | -$764K | 0.97% | 43 |
|
|
2016
Q4 | $6.35M | Buy |
45,000
+20,000
| +80% | +$2.95M | 1.22% | 32 |
|
|
2016
Q3 | $3.98M | Buy |
+25,000
| New | +$3.85M | 0.63% | 57 |
|
|
2015
Q3 | – | Sell |
-37,000
| Closed | -$4.8M | – | 97 |
|
|
2015
Q2 | $4.8M | Buy |
+37,000
| New | +$4.82M | 0.58% | 64 |
|
|
2015
Q1 | – | Sell |
-22,000
| Closed | -$2.76M | – | 91 |
|
|
2014
Q4 | $2.76M | Sell |
22,000
-27,000
| -55% | -$3.28M | 0.8% | 50 |
|
|
2014
Q3 | $5.96M | Buy |
49,000
+16,000
| +48% | +$1.95M | 1.75% | 14 |
|
|
2014
Q2 | $3.89M | Sell |
33,000
-1,394
| -4% | -$164K | 1.16% | 27 |
|
|
2014
Q1 | $4.14M | Buy |
34,394
+9,394
| +38% | +$1.12M | 1.24% | 26 |
|
|
2013
Q4 | $2.78M | Buy |
+25,000
| New | +$2.49M | 1.09% | 31 |
|
Other funds holding TMO
VCM
Rhenman & Partners Asset Management's TMO Position: Q1 2026 in Review
Rhenman & Partners Asset Management increased its Thermo Fisher Scientific (TMO) stake by 23% in Q1 2026, buying an estimated $4.18M and bringing the position to 41,340 shares worth $20.3M. The position accounts for 2.51% of the portfolio, ranked #7.
Rhenman & Partners Asset Management first reported a position in TMO in Q4 2013 and has held it in 39 quarters since. The position peaked at $34.3M in Q3 2021. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Rhenman & Partners Asset Management held 41,340 shares of Thermo Fisher Scientific worth $20.3M as of Q1 2026.
- Rhenman & Partners Asset Management bought 7,700 Thermo Fisher Scientific shares in Q1 2026, an estimated $4.18M.
- Thermo Fisher Scientific made up 2.51% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #7 holding.
- Rhenman & Partners Asset Management first reported a position in Thermo Fisher Scientific in Q4 2013 and has held it in 39 quarters since.
- Rhenman & Partners Asset Management's Thermo Fisher Scientific position peaked at $34.3M in Q3 2021.
- 2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.